What is the clinical evidence from this study?

Study design: Cohort. Population: Light-chain cardiac amyloidosis (AL-CA) (n=96). Intervention: Lower systolic blood pressure (SBP). Primary outcome: Mortality (HR 1.30, 95% CI 1.10-1.54, p=0.002).

What does this research mean for the field?

Lower systolic blood pressure is an independent predictor of mortality in light-chain cardiac amyloidosis and provides modest incremental prognostic value beyond the Mayo 2012 staging system. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate contemporary survival outcomes in light-chain cardiac amyloidosis and identify routine clinical predictors that improve established biomarker-based risk stratification systems.

September 28, 2026DiagnosticsOpen Access

Refining Risk Stratification in Light-Chain Cardiac Amyloidosis: A Single-Center Ambispective Cohort Study

View Full Paper

Ask AI

Bookmark

Key result

Lower SBP linked to ~30% higher mortality in light-chain cardiac amyloidosis.

HR 1.30
95% CI 1.10-1.54
P=0.002
n=96

Key Points

To evaluate contemporary survival outcomes in light-chain cardiac amyloidosis and identify routine clinical predictors that improve established biomarker-based risk stratification systems.
Ambispective single-center cohort study evaluating consecutive patients (N = 96) diagnosed with light-chain cardiac amyloidosis between 2014 and 2024.
Multivariable Cox proportional hazards regression and concordance index (C-index) comparisons evaluated predictors of all-cause mortality alongside the Mayo 2012 staging system.
During follow-up, 51 of 96 patients (53.1%) died.
Independent predictors of mortality included lower systolic blood pressure (HR 1.30, 95% CI 1.10–1.54; p = 0.002), troponin >3× the upper reference limit (HR 2.67, 95% CI 1.29–5.55; p = 0.008), and advanced NYHA class (HR 1.92, 95% CI 1.14–3.24; p = 0.014).
Incorporating systolic blood pressure into the Mayo 2012 staging system modestly improved discrimination (C-index: 0.685 vs. 0.723; ΔC-index = 0.038) and reduced prediction error.

Study Design

Type

Cohort (n=96)

Multicenter

PICO

Population

96 consecutive patients with light-chain cardiac amyloidosis diagnosed between 2014 and 2024.

Exposure / Comparator

Lower systolic blood pressure (SBP)

Primary Outcome

Mortality — HR 1.30 (1.10-1.54), p=0.002

Main Result

Hazard Ratio: 1.3 (95% CI 1.1–1.54)

p-value: p=0.002

Limitations

Added predictive value requires validation in larger independent cohorts

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports adding systolic blood pressure to Mayo staging in light-chain amyloidosis; hypothesis-generating and requires prospective validation.

Cite This Study

Özerdem et al. (2026) conducted a cohort in Light-chain cardiac amyloidosis (AL-CA) (n=96). Lower systolic blood pressure (SBP) was evaluated on Mortality (HR 1.30, 95% CI 1.10-1.54, p=0.002). Lower systolic blood pressure was an independent predictor of mortality in light-chain cardiac amyloidosis (HR 1.30; 95% CI 1.10-1.54; p=0.002).

synapsesocial.com/papers/6ab9b4957822ec8fc3d8e673 https://doi.org/10.3390/diagnostics16193111

Topics

Heart failure HFrEF treatment Cardiac amyloidosis

View Full Paper

Ask AI

Bookmark

Implication

Supports adding systolic blood pressure to Mayo staging in light-chain amyloidosis; hypothesis-generating and requires prospective validation.

Refining Risk Stratification in Light-Chain Cardiac Amyloidosis: A Single-Center Ambispective Cohort Study

Key Points

Study Design

PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Topics

Refining Risk Stratification in Light-Chain Cardiac Amyloidosis: A Single-Center Ambispective Cohort Study

Key Points

Study Design

PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Keep reading

Topics

Keep reading